% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hammes:140256,
      author       = {Hammes, Jochen and Drzezga, Alexander and Eimeren, Thilo},
      title        = {{T}he {R}ole of {T}au {I}maging in {P}arkinsonian
                      {D}isorders.},
      journal      = {Current neurology and neuroscience reports},
      volume       = {18},
      number       = {12},
      issn         = {1528-4042},
      address      = {Philadelphia, Pa.},
      publisher    = {Current Science Inc.},
      reportid     = {DZNE-2020-06578},
      pages        = {86},
      year         = {2018},
      abstract     = {Differential diagnosis of atypical Parkinson syndromes
                      (APS) is difficult as clinical presentations may vary and as
                      there is a strong overlap between disease entities.
                      Aggregations of misfolded and hyperphosphorylated tau
                      proteins are the common denominator of many of these
                      diseases.Several tau targeting positron emission tomography
                      (PET) tracers have been evaluated as possible biomarkers in
                      APS in the recent years. For Parkinson's disease, dementia
                      with Lewy bodies, progressive supranuclear palsy, and
                      corticobasal degeneration, promising results have been
                      reported with regard to the ability to detect the presence
                      of disease and to discriminate patients from controls.
                      However, the discussion about the specificity of the
                      first-generation radiotracers and their value in the
                      clinical context is ongoing. A combined interpretation of
                      signal strength and distribution pattern in PET scans with
                      first- and second-generation tracers may be helpful in
                      clinical diagnosis and follow-up of patients with APS.},
      subtyp        = {Review Article},
      keywords     = {Alzheimer Disease: diagnosis / Alzheimer Disease:
                      diagnostic imaging / Alzheimer Disease: metabolism /
                      Diagnosis, Differential / Humans / Parkinsonian Disorders:
                      diagnostic imaging / Parkinsonian Disorders: metabolism /
                      Positron-Emission Tomography: methods / Supranuclear Palsy,
                      Progressive: diagnosis / Supranuclear Palsy, Progressive:
                      diagnostic imaging / Supranuclear Palsy, Progressive:
                      metabolism / tau Proteins: metabolism / tau Proteins (NLM
                      Chemicals)},
      cin          = {AG Boecker / Patient studies, Bonn},
      ddc          = {610},
      cid          = {I:(DE-2719)1011202 / I:(DE-2719)1011101},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30293094},
      doi          = {10.1007/s11910-018-0898-3},
      url          = {https://pub.dzne.de/record/140256},
}